Skip to main content

In the largest clinical development program in
Dry Eye (N=2871)…
EYSUVIS Had a Low Incidence
of IOP Elevation Similar to Vehicle
and Was Well-Tolerated

  • Incidence of IOP elevation was low in patients using EYSUVIS and similar to vehicle1
    • EYSUVIS was dosed up to 29 days in 4 multicentered, randomized, double-masked, vehicle-controlled trials
    • Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, as well as defects in visual acuity and fields of vision. Corticosteroids should be used with caution in the presence of glaucoma. Renewal of the medication order should be made by a physician only after examination of the patient and evaluation of the IOP
Number (%) of Patients With
IOP Elevation Compared With Baseline
at Any Postbaseline Visit
EYSUVIS
(n=1430)
Vehicle
(n=1438)
> 5 mm Hg increase from BL and ≥ 21 mm Hg 9 (0.6%) 3 (0.2%)
≥ 10 mm Hg increase from BL and ≥ 21 mm Hg 3 (0.2%) 0

BL=baseline.

  • The treatment-related adverse event reported in ≥1% of patients was instillation site pain, which was reported in 5% of patients using EYSUVIS vs 4% with vehicle and was mild to moderate in severity1

Peer-Reviewed Publication

Reference: 1. Korenfeld M, Nichols KK, Goldberg D, et al. Safety of KPI-121 ophthalmic suspension 0.25% in patients with dry eye disease: a pooled analysis of 4 multicenter, randomized, vehicle-controlled studies. Cornea. 2020. In press.

Important Safety Information

Contraindication:

EYSUVIS, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

Warnings and Precautions:

Delayed Healing and Corneal Perforation: Topical corticosteroids have been known to delay healing and cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. The initial prescription and each renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining.

Intraocular Pressure (IOP) Increase: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, as well as defects in visual acuity and fields of vision. Corticosteroids should be used with caution in the presence of glaucoma. Renewal of the medication order should be made by a physician only after examination of the patient and evaluation of the IOP.

Cataracts: Use of corticosteroids may result in posterior subcapsular cataract formation.

Bacterial Infections: Use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, corticosteroids may mask infection or enhance existing infection.

Viral Infections: Use of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion must be considered in any persistent corneal ulceration where a corticosteroid has been used or is in use.

Adverse Reactions:

The most common adverse drug reaction following the use of EYSUVIS for two weeks was instillation site pain, which was reported in 5% of patients.

Indication

EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.

View full Prescribing Information(opens a PDF document in a new window).